New Publications: Dysarthria and Dietary Fats

Blog Science

In this blog post, I want to talk about two recent publications in our community. The first publication is “GLUT1DS focus on dysarthria” by the team of Dr. Valentina De Giorgis in Italy. This publication talks about a study which purpose was to analyze and characterize the speech profile of a sample of patients with GLUT1 Deficiency from school age to adulthood. This was an observational study that included 30 patients with GLUT1 Deficiency. The authors described that their results suggest that patients with GLUT1 Deficiency would benefit from a comprehensive neurocognitive assessment to detect strengths and weaknesses of the speech profile. In addition, they mentioned that understanding the speech and language phenotype in GLUT1 Deficiency is critical for planning early intervention to positively influence the global development of these patients.

The last publication I wanted to mention is “Analysis of dietary fats intake and lipid profile in Chilean patients with glucose transport type 1 deficiency syndrome: similarities and differences with the reviewed literature” by the team of Dr. Veronica Cornejo in Chile. The aim of this study, was to describe the types of fats ingested by the Chilean cohort of GLUT1 Deficiency patients and determine if there was a relation with lipid profile. The study included 13 GLUT1 Deficiency patients who had been on the ketogenic dietary therapy (KDT) for at least a year, and who had a genetic study of the SLC2A1 gene. Their results showed that patients followed a high-fat diet, especially with saturated fat. In addition, participants had a higher intake of monounsaturated (MUFA) and polyunsaturated fats (PUFA), and that there were no significant differences in the lipid and liver profile compared to the control group. The authors concluded that the KDT did not negatively impact the lipid profile, and that is important to monitor lipid profiles in a personalized and constant manner, to prevent future nutritional risks. Finally, the authors recommend that the KDT should always consider the use of Medium Chain Triglyceride (MCT), and provide 50% of total fats as MUFA + PUFA, especially Eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Finally, the authors suggest continuous monitoring of patients in the clinic.

Thank you to Dr. De Giorgis and Dr. Cornejo for their work to support our community,

Please do not hesitate to contact me at [email protected], if you have any questions.